| |
Newsroom /
Medical
/
Medical
/
Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
The Atrial Fibrillation Market is Forecast to Show Significant Growth until 2016
Hyderabad,
AP,
India
(prbd.net)
14/02/2010
"Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016"
The atrial fibrillation (AF) market is currently on the brink of rapid expansion due to the expected launch of novel products between 2010 and 2016 with new first-in-class molecules likely to replace the age-old generics which have been dominating the market, chiefly due to their low costs and a lack of suitable alternatives. The latest entrant into the market was Multaq in 2009. It was launched after the loss of patent protection for Sanofi-Aventis's previous anti-arrythmic drug, Cordarone (amiodarone) in the US in 2002. The presently marketed products have numerous adverse events and associated toxic side-effects. It would, therefore, be sufficient for newer entrants to demonstrate a superior efficacy and safety profile in order to capture value in the market from the currently used generic drugs.
GlobalData’s in-depth analysis reveals that Stedicor is likely to dominate the future AF market followed by Kynapid, given that there were numerous safety related concerns over Multaq in patients. Nevertheless, the market is all set to witness a definite paradigm shift in the treatment of atrial fibrillation with the entry of new products that would command higher prices owing to their clinical superiority. Increase in the treatment seeking population, prescription rates and an increase in the ageing global population are considered to be important drivers for this market. A high projected growth rate is primarily attributable to the potentially strong late stage pipeline. Availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the atrial fibrillation market.
GlobalData found the current competition in the atrial fibrillation market to be weak as the market is mainly governed by generics that have comparable safety and efficacy profiles. This apart, major revenue for this market are generated by anticoagulants, which are prescribed in addition to anti-arrythmics to achieve a superior rate of rhythm control in patients. The anticoagulants market is in itself set to witness a remarkable growth rate with the approval of newer oral anticoagulants. The entry of these newer classes of drugs will undoubtedly accelerate the growth of the atrial fibrillation market also and annul the use of warfarins and other vitamin K antagonists. This would, in turn, start a race among the new entrants to capture value in the market and kick-start a phase of unprecedented growth. Procter and Gamble’s (P & G’s) Stedicor is expected to lead sales in the atrial fibrillation market in the next few years. However, other products, such as Multaq, Pradaxa, and Xarelto are likely to give strong competition to Stedicor. The entry of newer atrial fibrillation agents would propel the growth of the market forward, with an estimated quadrupling of the current market revenues.
GlobalData, the industry analysis specialist’s new report, “Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global atrial fibrillation market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global atrial fibrillation sector.
Visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|